Claims for Patent: 9,090,664

Summary for Patent: 9,090,664

Title:	Composition for long-acting peptide analogs
Abstract:	The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm).sub.x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (Z.sub.yHis.sub.w).sub.p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
Inventor(s):	Castillo; Gerardo M. (Bothell, WA), Bolotin; Elijah M. (Bothell, WA)
Assignee:	PharmaIN Corporation (Bothell, WA)
Application Number:	13/952,411
Patent Claims:	1. A composition comprising a peptide analog having a general formula: A-(Cm)x-(peptide), wherein: a. Cm is each independently lysine or arginine; b. x is an integer from 3-6; c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl and amino; and d. the peptide is selected from vasopressin or a derivative thereof, terlipressin or a derivative thereof, glucagon like peptide (GLP), leptin fragment, gastric inhibitory polypeptide (GIP), epidermal growth factor (EGF) receptor ligand, EGF, transforming growth factor alpha (TGF-alpha), gastrin/cholecystokinin receptor ligand, gastrin, cholecystokinin, auristatin, nisin, insulin, insulin-like growth factor, parathyroid hormone (PTH), atrial natriuretic factor, somatostatin, gonadotropin releasing hormone, leutinizing-hormone-releasing-hormone, and vasoactive intestinal peptide (VIP). 2. The composition of claim 1, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 3. The composition of claim 2, wherein the peptide is selected from the group consisting of terlipressin and derivatives thereof and atrial natriuretic factor, and A-(Cm)x- is attached to the N terminus of the peptide. 4. The composition of claim 2, wherein the peptide is vasoactive intestinal peptide (VIP) or atrial natriuretic factor and A-(Cm)x- is attached to the C terminus of the peptide or a side chain. 5. The composition of claim 2, wherein A is a linear alkyl. 6. The composition of claim 3, wherein A is a linear alkyl. 7. The composition of claim 4, wherein A is a linear alkyl. 8. The composition of claim 2, wherein A is a branched alkyl. 9. The composition of claim 3, wherein A is a branched alkyl. 10. The composition of claim 4, wherein A is a branched alkyl. 11. The composition of claim 1, wherein the peptide is selected from the group consisting of terlipressin and derivatives thereof and atrial natriuretic factor, and A-(Cm)x is attached to the N terminus of the peptide. 12. The composition of claim 1, wherein A is a linear alkyl. 13. The composition of claim 11, wherein A is a linear alkyl. 14. The composition of claim 1, wherein A is a branched alkyl. 15. The composition of claim 11, wherein A is a branched alkyl. 16. A method of making a peptide analog composition of claim 1, comprising: step (i): forming a covalent bond between a resin and a reactive group on a first amino acid to provide a resin comprising a covalently bonded amino acid; step (ii): forming a covalent bond between the resin comprising the covalently bonded amino acid and a reactive group on a second amino acid; step (iii): repeating step (ii) to provide a (Cm)x-peptide; and forming a carbonyl or amino bond between the (Cm)x-peptide and an alkyl group with 6 to 36 carbon units to provide a peptide analog according to claim 1. 17. A method for treatment of hypovolemia, ascites, splanchnic vasodilation, systemic vasodilation, hypotension, esophageal variceal hemorrhage, hepatorenal syndrome, or sepsis in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising a composition of claim 1 in pharmaceutically acceptable carrier wherein the peptide comprises sequence ID 53. 18. The composition of claim 1, wherein the A-(Cm)x-(peptide) has lower biological activity in cell culture than the parent peptide in the absence of serum. 19. A composition comprising a peptide analog having a general formula: A-(Cm)x-(peptide), wherein: a. Cm is each independently lysine, glycine, or arginine; b. x is an integer from 2-6; c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl and amino; and d. the peptide comprises atrial natriuretic factor. 20. The composition of claim 19, wherein the peptide is atrial natriuretic factor. 21. The composition of claim 19, wherein x is 3 or 4. 22. The composition of claim 19, wherein Cm is each independently lysine or glycine. 23. The composition of claim 19, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 24. The composition of claim 1, wherein the peptide is vasopressin or a derivative thereof. 25. The composition of claim 24, wherein the peptide is vasopressin. 26. The composition of claim 24, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 27. The composition of claim 1, wherein the peptide is terlipressin or a derivative thereof. 28. The composition of claim 27, wherein the peptide is terlipressin. 29. The composition of claim 27, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 30. The composition of claim 1, wherein the peptide is glucagon like peptide (GLP). 31. The composition of claim 30, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 32. The composition of claim 1, wherein the peptide is atrial natriuretic factor. 33. The composition of claim 32, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 34. The composition of claim 1, wherein the peptide is vasoactive intestinal peptide (VIP). 35. The composition of claim 34, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction. 36. The composition of claim 1, wherein the peptide is epidermal growth factor (EGF) receptor ligand. 37. The composition of claim 36, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction.

Details for Patent 9,090,664

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2027-08-03